

Kevin M Elias

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7900240/kevin-m-elias-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

3,346
citations

23
h-index

57
g-index

121
ext. papers

4,121
ext. citations

5
avg, IF

5.14
L-index

#	Paper	IF	Citations
96	Pharmacotherapeutic prophylaxis and post-operative outcomes within an Enhanced Recovery After Surgery (ERAS [®]) program: A randomized retrospective cohort study.. <i>Annals of Medicine and Surgery</i> , 2022 , 73, 103178	2	0
95	Isolation and culture of decidual natural killer cells from term placenta and complete hydatidiform mole.. <i>Journal of Reproductive Immunology</i> , 2022 , 150, 103475	4.2	
94	The Loop Electrosurgical Excision Procedure and Cone Conundrum: The Role of Cumulative Excised Depth in Predicting Preterm Birth.. <i>AJP Reports</i> , 2022 , 12, e41-e48	1.2	
93	Consolidation chemotherapy in postmolar low-risk gestational trophoblastic neoplasia: a systematic review protocol.. <i>BMJ Open</i> , 2022 , 12, e059484	3	
92	Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer.. <i>Journal of Ovarian Research</i> , 2022 , 15, 28	5.5	0
91	A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers.. <i>Frontiers in Oncology</i> , 2022 , 12, 786154	5.3	
90	Fast and robust imputation for miRNA expression data using constrained least squares.. <i>BMC Bioinformatics</i> , 2022 , 23, 145	3.6	
89	A termSzetes Bejtek szerepe az anyai-magzati immunhomeostasis fenntartásban.. <i>Orvosi Hetilap</i> , 2022 , 163, 734-742	0.8	1
88	Audit of compliance and clinical outcomes 2022 , 237-245		
87	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. <i>Cancer Research</i> , 2021 , 81, 158-173	10.1	27
86	Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy. <i>Clinics</i> , 2021 , 76, e2830	2.3	
85	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 ,	4	2
84	A novel alternative to cytotoxic chemotherapy for gestational trophoblastic disease. <i>Lancet Oncology</i> , 2021 , 22, 1490-1491	21.7	1
83	Enhanced recovery after surgery protocols improve time to return to intended oncology treatment following interval cytoreductive surgery for advanced gynecologic cancers. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1145-1153	3.5	4
82	Treatment of hydatidiform mole using manual vacuum aspiration: technical and tactical aspects. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1299-1300	3.5	
81	Loss of Selenoprotein Iodothyronine Deiodinase 3 Expression Correlates with Progression of Complete Hydatidiform Mole to Gestational Trophoblastic Neoplasia. <i>Reproductive Sciences</i> , 2021 , 28, 3200-3211	3	1
80	Treatment of high-risk gestational trophoblastic neoplasia and chemoresistance/relapsed disease. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2021 , 74, 81-96	4.6	6

79	Distinct microRNA profiles for complete hydatidiform moles at risk of malignant progression. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 224, 372.e1-372.e30	6.4	7
78	Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study. <i>Current Problems in Cancer</i> , 2021 , 45, 100622	2.3	2
77	Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. <i>American Journal of Reproductive Immunology</i> , 2021 , 86, e13394	3.8	1
76	Challenges in the Treatment of Low-risk Gestational Trophoblastic Neoplasia. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2021 , 43, 503-506	1.1	0
75	Video Hysteroscopy in the Diagnosis of Molar Pregnancy in two Challenging Situations: Complete Mole with Normal hCG and Partial Mole with Early Gestational Age. <i>Journal of Minimally Invasive Gynecology</i> , 2021 , 28, 1448-1449	2.2	
74	Risk of venous thromboembolism for ovarian cancer patients during first-line therapy after implementation of an Enhanced Recovery After Surgery (ERAS) protocol. <i>Gynecologic Oncology</i> , 2021 , 162, 353-359	4.9	2
73	Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. <i>Lancet Oncology, The</i> , 2021 , 22, 1188-1198	21.7	11
72	Synthetic Lethality in Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2117-2128	6.1	6
71	Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?. <i>Gynecologic Oncology</i> , 2021 , 162, 638-644	4.9	1
70	Perioperative glycemic measures among non-fasting gynecologic oncology patients receiving carbohydrate loading in an enhanced recovery after surgery (ERAS) protocol. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 533-540	3.5	3
69	Outcomes in the management of high-risk gestational trophoblastic neoplasia in trophoblastic disease centers in South America. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1366-1371	3.5	2
68	EMA vs EMACO in the treatment of gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2020 , 158, 99-104	4.9	3
67	Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study. <i>Gynecologic Oncology</i> , 2020 , 158, 452-459	4.9	14
66	Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2020 , 157, 372-378	4.9	8
65	Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. <i>Gynecologic Oncology</i> , 2020 , 156, 598-605	4.9	5
64	Association between antioxidant vitamins and oxidative stress among patients with a complete hydatidiform mole. <i>Clinics</i> , 2020 , 75, e1724	2.3	2
63	Research Methods in Enhanced Recovery After Surgery 2020 , 351-360		
62	Outcomes for relapsed versus resistant low risk gestational trophoblastic neoplasia following single-agent chemotherapy. <i>Gynecologic Oncology</i> , 2020 , 159, 751-757	4.9	0

61	Expanding Pharmacotherapy Data Collection, Analysis, and Implementation in ERAS Programs-The Methodology of an Exploratory Feasibility Study. <i>Healthcare (Switzerland)</i> , 2020 , 8,	3.4	1
60	Educating healthcare providers to increase Human Papillomavirus (HPV) vaccination rates: A Qualitative Systematic Review. <i>Vaccine: X</i> , 2019 , 3, 100037	3.8	34
59	International validation of Enhanced Recovery After Surgery Society guidelines on enhanced recovery for gynecologic surgery. <i>American Journal of Obstetrics and Gynecology</i> , 2019 , 221, 237.e1-237.e11	6.4	57
58	Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer. <i>Bioengineering and Translational Medicine</i> , 2019 , 4, e10131	14.8	18
57	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , 2019 , 125, 1963-1972	6.4	22
56	Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?. <i>Gynecologic Oncology</i> , 2019 , 153, 277-285	4.9	12
55	Liquid biopsy of HPV DNA in cervical cancer. <i>Journal of Clinical Virology</i> , 2019 , 114, 32-36	14.5	22
54	Guidelines for perioperative care in gynecologic/oncology: Enhanced Recovery After Surgery (ERAS) Society recommendations-2019 update. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 651-668	3.5	216
53	The Reporting on ERAS Compliance, Outcomes, and Elements Research (RECOVER) Checklist: A Joint Statement by the ERAS and ERAS USA Societies. <i>World Journal of Surgery</i> , 2019 , 43, 1-8	3.3	97
52	Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2019 , 154, 595-601	4.9	13
51	Defining fallopian tube-derived miRNA cancer signatures. <i>Cancer Medicine</i> , 2019 , 8, 6709-6716	4.8	7
50	State-of-the-Art Workup and Initial Management of Newly Diagnosed Molar Pregnancy and Postmolar Gestational Trophoblastic Neoplasia. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1396-1401	7.3	10
49	Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018 , 223, 50-55	2.4	3
48	Gestational Trophoblastic Disease Electronic Consults: What Do Patients and Physicians Want to Know?. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 824-828	3.5	4
47	Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute. <i>Gynecologic Oncology</i> , 2018 , 148, 5-11	4.9	11
46	Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?. <i>Gynecologic Oncology</i> , 2018 , 148, 239-246	4.9	7
45	RNA-Peptide nanoplexes drug DNA damage pathways in high-grade serous ovarian tumors. <i>Bioengineering and Translational Medicine</i> , 2018 , 3, 26-36	14.8	9
44	Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience. <i>Gynecologic Oncology</i> , 2018 , 148, 161-167	4.9	34

43	Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. <i>Cancer Treatment Reviews</i> , 2018 , 69, 66-71	14.4	9
42	Experience With the Use of an Online Community on Facebook for Brazilian Patients With Gestational Trophoblastic Disease: Netnography Study. <i>Journal of Medical Internet Research</i> , 2018 , 20, e10897	7.6	5
41	Early Detection of Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018 , 32, 903-914	3.1	53
40	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. <i>Journal of Pathology</i> , 2018 , 246, 459-469	9.4	15
39	Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. <i>Gynecologic Oncology</i> , 2017 , 145, 88-95	4.9	38
38	Association between peak estradiol levels and ovarian torsion among symptomatic patients receiving gonadotropin treatment. <i>Journal of Assisted Reproduction and Genetics</i> , 2017 , 34, 627-631	3.4	6
37	Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women. <i>Gynecologic Oncology</i> , 2017 , 146, 334-339	4.9	22
36	Long term mortality in critically ill burn survivors. <i>Burns</i> , 2017 , 43, 1155-1162	2.3	14
35	Sentinel lymph node mapping reduces practice pattern variations in surgical staging for endometrial adenocarcinoma: A before and after study. <i>Gynecologic Oncology</i> , 2017 , 145, 248-255	4.9	8
34	Type I interferons modulate methotrexate resistance in gestational trophoblastic neoplasia. <i>American Journal of Reproductive Immunology</i> , 2017 , 77, e12666	3.8	9
33	Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?. <i>Gynecologic Oncology</i> , 2017 , 147, 364-370	4.9	11
32	Understanding Enhanced Recovery After Surgery Guidelines: An Introductory Approach. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2017 , 27, 871-875	2.1	13
31	Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. <i>ELife</i> , 2017 , 6,	8.9	70
30	Is chemotherapy necessary for patients with molar pregnancy and human chorionic gonadotropin serum levels raised but falling at 6months after uterine evacuation?. <i>Gynecologic Oncology</i> , 2016 , 143, 558-564	4.9	9
29	Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery?. <i>Gynecologic Oncology</i> , 2016 , 142, 255-60	4.9	25
28	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. <i>Cell Reports</i> , 2016 , 14, 429-439	10.6	91
27	Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. <i>JCI Insight</i> , 2016 , 1,	9.9	28
26	Changing Trends in the Clinical Presentation and Management of Complete Hydatidiform Mole Among Brazilian Women. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 984-90	3.5	14

25	A prognostically relevant miRNA signature for epithelial ovarian cancer. <i>Lancet Oncology, The</i> , 2016 , 17, 1032-1033	21.7	9
24	Functional status, age, and long-term survival after trauma. <i>Surgery</i> , 2016 , 160, 762-70	3.6	7
23	Apoptotic index for prediction of postmolar gestational trophoblastic neoplasia. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 215, 336.e1-336.e12	6.4	9
22	Centralized Coordination of Decentralized Assistance for Patients with Gestational Trophoblastic Disease in Brazil: A Viable Strategy for Developing Countries. <i>Journal of reproductive medicine, The</i> , 2016 , 61, 224-9		5
21	Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1341-8	3.1	29
20	Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. <i>Oncogene</i> , 2015 , 34, 373-83	9.2	31
19	Derivation and validation of the acute organ failure score to predict outcome in critically ill patients: a cohort study. <i>Critical Care Medicine</i> , 2015 , 43, 856-64	1.4	42
18	Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation. <i>Gynecologic Oncology</i> , 2015 , 139, 283-7	4.9	11
17	Beyond genomics: critical evaluation of cell line utility for ovarian cancer research. <i>Gynecologic Oncology</i> , 2015 , 139, 97-103	4.9	52
16	Association between pre-hospital vitamin D status and hospital-acquired new-onset delirium. <i>British Journal of Nutrition</i> , 2015 , 113, 1753-60	3.6	12
15	GATA3 expression in gestational trophoblastic tissues and tumours. <i>Histopathology</i> , 2015 , 67, 636-44	7.3	28
14	The authors reply. <i>Critical Care Medicine</i> , 2015 , 43, e399-400	1.4	
13	Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women. <i>International Journal of Cancer</i> , 2015 , 137, 776-83	7.5	33
12	Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. <i>Gynecologic Oncology</i> , 2014 , 132, 328-33	4.9	14
11	Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2611-25	15.9	84
10	Complete hydatidiform mole in women aged 40 to 49 years. <i>Journal of reproductive medicine, The</i> , 2012 , 57, 254-8		17
9	Matrix metalloproteinases and their inhibitors and inducer in gestational trophoblastic diseases and normal placenta. <i>Gynecologic Oncology</i> , 2011 , 122, 178-82	4.9	16
8	Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase II Trial in women with recurrent or persistent carcinosarcomas of the uterus. <i>Gynecologic Oncology</i> , 2010 , 117, 248-54	4.9	33

7	Complete hydatidiform mole in women older than age 50. <i>Journal of reproductive medicine, The</i> , 2010 , 55, 208-12		16
6	Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. <i>Nature</i> , 2008 , 452, 773-6	50.4	926
5	Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. <i>Blood</i> , 2008 , 111, 1013-20	2.2	346
4	Molecular and Cellular Basis of Immunity and Immunological Diseases 2008 , 94-107		0
3	IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. <i>Journal of Biological Chemistry</i> , 2007 , 282, 34605-10	5.4	482
2	Biomarker discovery in epithelial ovarian cancer by genomic approaches. <i>Advances in Cancer Research</i> , 2007 , 96, 1-22	5.9	11
1	Oncofertility: a Review. <i>Current Obstetrics and Gynecology Reports</i> ,1		0.6